Allergan plc (AGN)


NYSE - NYSE Real Time Price. Currency in USD
234.05-9.22 (-3.79%)
As of 2:46 PM EDT. Market open.
People also watch:
BIIBCELGVRXGILDREGN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open243.00
Prev Close243.27
Bid234.09 x 100
Ask234.26 x 100
Day's Range232.10 - 244.27
52wk Range195.50 - 322.68
1y Target EstN/A
Market Cap92.67B
P/E Ratio (ttm)22.28
Beta1.11
Volume4,338,224
Avg Vol (3m)3,123,604
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Moody's13 minutes ago

    Teva Pharmaceutical Industries Ltd -- Moody's: Teva's Loss of Two Copaxone Patents is Credit Negative

    New York, August 25, 2016-- Moody's Investors Service commented that the Patent Trial and Appeal Board's invalidation of two of Teva's patents on Copaxone 40 mg is credit negative. However, there is no ...

  • Barrons.com1 hour ago

    Specialty Pharma: Never Mind the Pricing Controversy, Fundamentals Will Win Out

    While fundamentals of the group appear stable following the recent 2Q16 earnings season (see our recent note here) and valuations are attractive, we acknowledge that ongoing negative headlines may stunt the fledgling “recovery” that has started to take place in the space over the past couple of months. More broadly, while media scrutiny/political headlines around drug pricing could result in continued volatility through the elections, we continue to see the group positioned for a recovery over time, with valuations inexpensive on almost any metric (~8x 2017 EPS) and improving fundamentals after a challenging 1H/16.

  • Allergan, Humana, Biogen: Billionaires’ Favorite Healthcare Stocks For Q3
    Insider Monkey5 hours ago

    Allergan, Humana, Biogen: Billionaires’ Favorite Healthcare Stocks For Q3

    The healthcare sector had one of its worst years in almost a decade last year when several big names from the space saw their stocks plunge dramatically. The beginning of 2016 was equally dismal for several healthcare stocks, but they have managed to recoup some of the losses they suffered last year over the past […]